Henning Scheich
Fundador en Leibniz Institute for Neurobiology .
Cargos activos de Henning Scheich
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| Leibniz Institute for Neurobiology | Fundador | 31/08/2009 | - |
| Corporate Officer/Principal | 31/08/2009 | - | |
| Germany Ministry of Education & Research | Corporate Officer/Principal | 31/08/2009 | - |
Historial de carrera de Henning Scheich
Antiguos cargos conocidos de Henning Scheich.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
KeyNeurotek Pharmaceuticals AG
 KeyNeurotek Pharmaceuticals AG Pharmaceuticals: OtherHealth Technology KeyNeurotek Pharmaceuticals AG is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s drug portfolio covers the entire drug development chain from research stage to advanced clinical development. At present, two compounds are in clinical development, KN38-7271 and KN203, both addressing significant markets such as traumatic brain injury, TBI, stroke, and urinary incontinence/overactive bladder. The company’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system, TELOMICS. KeyNeurotek was founded by Dr Frank Striggow, Frank Baumgart, Prof Dr Klaus G. Reymann and Prof Dr Henning Scheich in May 2000. The company is located in Magdeburg, Germany. | Director/Miembro de la Junta | 31/08/2009 | 03/08/2011 |
| Fundador | 31/08/2009 | 03/08/2011 |
Estadísticas
Internacional
| Alemania | 4 |
Operativa
| Corporate Officer/Principal | 2 |
| Founder | 2 |
| Director/Board Member | 1 |
Sectorial
| Health Technology | 2 |
| Government | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 3 |
|---|---|
KeyNeurotek Pharmaceuticals AG
KeyNeurotek Pharmaceuticals AG Pharmaceuticals: OtherHealth Technology KeyNeurotek Pharmaceuticals AG is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s drug portfolio covers the entire drug development chain from research stage to advanced clinical development. At present, two compounds are in clinical development, KN38-7271 and KN203, both addressing significant markets such as traumatic brain injury, TBI, stroke, and urinary incontinence/overactive bladder. The company’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system, TELOMICS. KeyNeurotek was founded by Dr Frank Striggow, Frank Baumgart, Prof Dr Klaus G. Reymann and Prof Dr Henning Scheich in May 2000. The company is located in Magdeburg, Germany. | Health Technology |
| Leibniz Institute for Neurobiology | |
| Germany Ministry of Education & Research | Government |
- Bolsa de valores
- Insiders
- Henning Scheich
- Experiencia
